Concerta vs Vyvanse
Concerta (methylphenidate ER) and Vyvanse (lisdexamfetamine) are both long-acting, once-daily Schedule II stimulants used for attention-deficit/hyperactivity disorder (ADHD). They represent the two major classes of ADHD stimulant medications — methylphenidate-based and amphetamine-based — and differ substantially in their mechanism, prodrug design, duration of effect, and additional approved uses. Understanding how they differ helps patients and prescribers make informed decisions when starting or switching ADHD therapy.
Quick Comparison
| Feature | Methylphenidate ER (Concerta) | Lisdexamfetamine (Vyvanse) |
|---|---|---|
| Drug Class | Methylphenidate (non-amphetamine CNS stimulant) | Amphetamine prodrug (CNS stimulant) |
| Generic Name | Methylphenidate hydrochloride ER | Lisdexamfetamine dimesylate |
| Brand Name | Concerta | Vyvanse |
| Approved For | ADHD (ages 6 and older) | ADHD (ages 6 and older); binge eating disorder (adults) |
| Available as Generic | Yes (with notable bioequivalence concerns for some generics) | Yes (generic lisdexamfetamine available) |
| Key Advantage | OROS technology provides consistent 12-hour delivery; different mechanism useful when amphetamines not tolerated; long safety history | Prodrug design lowers abuse potential (requires enzymatic activation); ~14-hour duration; also approved for binge eating disorder; amphetamines generally considered more potent |
| Main Drawback | Some generic OROS formulations have had bioequivalence controversy; may be less potent than amphetamines in some patients; no non-ADHD indication | Still Schedule II despite prodrug design; converted to d-amphetamine (cannot use in amphetamine allergy); no generic of the brand device (though generic active ingredient available) |
How They're Similar
Both Concerta and Vyvanse are DEA Schedule II controlled substances, reflecting their high abuse potential within the stimulant class. Both increase the availability of dopamine and norepinephrine in the brain, improving attention, impulse control, and executive function in patients with ADHD. Both are once-daily oral formulations designed to provide coverage throughout the school or work day, and both require a written prescription that cannot be called in or refilled without a new prescription in most states.
Both carry class-wide warnings: cardiovascular risks (increased heart rate and blood pressure), potential for psychiatric effects (psychosis, mania), growth suppression in children with prolonged use, and risk of dependence. Prescribers typically monitor blood pressure, heart rate, and growth in children during treatment.
Key Differences
Drug class — methylphenidate vs amphetamine: This is the fundamental distinction. Methylphenidate (Concerta's active ingredient) primarily blocks dopamine and norepinephrine reuptake. Amphetamines (Vyvanse converts to d-amphetamine) both block reuptake AND actively promote the release of dopamine and norepinephrine from nerve terminals — a more potent mechanism. This is why amphetamines are generally considered more potent stimulants per milligram and why patients who do not respond to methylphenidate may respond to amphetamines and vice versa.
Prodrug design: Vyvanse contains lisdexamfetamine — a therapeutically inactive compound that must be cleaved by enzymes (peptidases) in red blood cells to release active d-amphetamine. This prodrug approach means that crushing, snorting, or injecting Vyvanse does not produce the rapid drug delivery that fuels misuse — the enzymatic conversion still rate-limits absorption. This makes Vyvanse pharmacologically designed with reduced abuse potential compared to other amphetamine formulations, despite remaining Schedule II.
Delivery technology: Concerta uses OSMOTIC RELEASE ORAL SYSTEM (OROS) technology — a sophisticated osmotic pump system that delivers approximately 22% of the dose immediately and 78% continuously over 10–12 hours. This provides a sustained, ascending release pattern. Generic versions of Concerta using non-OROS technology have been controversial, as some have not demonstrated equivalent clinical performance, and the FDA has issued communications about this concern.
Additional indications: Vyvanse is the only stimulant medication FDA-approved for binge eating disorder (BED) in adults, representing a meaningful expansion beyond ADHD. Concerta has no approved indication beyond ADHD.
Duration: Concerta provides approximately 12 hours of coverage. Vyvanse, due to the enzymatic conversion kinetics, provides approximately 14 hours — among the longest durations of any stimulant formulation. This may benefit adults who need coverage through evening hours.
Methylphenidate (Concerta): Strengths & Weaknesses
Strengths: OROS technology provides consistent delivery, long safety track record, different mechanism from amphetamines (useful when amphetamines are not tolerated or contraindicated), generally generic versions available at lower cost.
Weaknesses: Some patients respond better to amphetamines. Generic OROS bioequivalence controversies mean brand Concerta may perform differently than some generics. No non-ADHD approved indication.
Lisdexamfetamine (Vyvanse): Strengths & Weaknesses
Strengths: Prodrug design reduces misuse potential; longer duration (~14h); FDA-approved for binge eating disorder; generally considered more potent for symptom control in many patients; smooth onset and offset due to prodrug kinetics.
Weaknesses: Amphetamine class — not appropriate in patients with allergy or intolerance to amphetamines. Still Schedule II. Appetite suppression and insomnia may be more pronounced than methylphenidate in some patients. Historically more expensive.
Frequently Asked Questions
Which is stronger, Concerta or Vyvanse?
Amphetamines are generally considered more potent stimulants than methylphenidate on a per-milligram basis. Many patients report subjectively stronger effects with Vyvanse. However, individual response varies significantly — some patients do better on methylphenidate, and prescribers typically try one class before switching to the other if the first is inadequate or poorly tolerated.
Why is Vyvanse considered less abusable if it's still Schedule II?
The prodrug design limits the rapid peak in drug blood levels that is associated with euphoria and misuse — it cannot be administered intranasally or intravenously to bypass the slow enzymatic conversion. However, it is still misused at high oral doses and remains Schedule II because abuse is still possible, and the drug produces active amphetamine. The prodrug design reduces, but does not eliminate, abuse potential.
Are there generic versions of Concerta that work the same?
The FDA has noted that generic methylphenidate ER products using non-OROS technology may not deliver medication identically to brand Concerta. Some patients and clinicians have reported clinical differences. The FDA issued communications suggesting that substituting non-OROS generics for OROS-based Concerta may require clinical monitoring. Discuss with your prescriber if you are experiencing differences after a generic substitution.
Can you take Concerta and Vyvanse together?
Combining two stimulants is not standard practice and generally not recommended. It significantly increases cardiovascular risks and the potential for psychiatric side effects. In rare, highly specialized circumstances a psychiatrist might use augmentation strategies, but this is well outside routine clinical practice.
Related Pages
⚠ This comparison is for informational purposes only. Never start, stop, or switch medications without guidance from a licensed healthcare provider. Individual responses to medication vary significantly.